Research Overview

Our research focusses on investigating the role of anti-tumour immunity (Type I Interferon activation in the tumour microenvironment) in therapeutic response. Using ovarian and bladder cancer patient derived specimens, cell lines and immunocompetent mouse models to study the tumour-immune interactions, the primary goals of our research program are,

  1. To define the role of sexual dimorphism and aging in anti-tumour immunity and treatment outcomes.
  2. To delineate the role of cancer cell intrinsic genetic events, such as DNA damage repair deficiency, in the evolution of distinct immune microenvironment landscapes.
  3. To develop combination immune priming approaches to enhance sensitivity to chemotherapy and immune checkpoint blockade therapy.
  4. To develop improved non-invasive immune monitoring approaches and biomarkers for application as prognostic and predictive indicators for personalized treatment of cancer.

Dr. Koti is a Veterinarian with PhD in Immunology. She is currently an Assistant Professor in the Departments of Biomedical and Molecular Sciences and Obstetrics and Gynaecology at Queen’s University. She is also cross-appointed to the Department of Urology and is a member of the Division of Cancer Biology and Genetics at QCRI.

The Koti Laboratory is located at the Queen’s Cancer Research Institute (QCRI). The QCRI is constituted by Cancer Biology and Genetics, Cancer Care and Epidemiology and Cancer Clinical Trials.

                                                                                          RESEARCH FUNDED BY 

Assistant Professor
Dr. Madhuri Koti, DVM, MVSc, PhD